These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17948847)

  • 21. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
    Manzoni P; Leonessa M; Farina D; Gomirato G
    Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
    [No Abstract]   [Full Text] [Related]  

  • 22. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention of respiratory syncytial virus infections].
    Rossi GA
    Minerva Pediatr; 2002 Apr; 54(2):75-8. PubMed ID: 11981522
    [No Abstract]   [Full Text] [Related]  

  • 25. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 30. Strategies for prevention of RSV nosocomial infection.
    Groothuis J; Bauman J; Malinoski F; Eggleston M
    J Perinatol; 2008 May; 28(5):319-23. PubMed ID: 18368056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prophylaxis against RS virus infection].
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Lakartidningen; 2002 Jan; 99(3):170-1. PubMed ID: 11838073
    [No Abstract]   [Full Text] [Related]  

  • 32. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consideration of palivizumab not justified.
    Clifford RD
    Thorax; 2006 Jun; 61(6):545-6; author reply 546. PubMed ID: 16738045
    [No Abstract]   [Full Text] [Related]  

  • 34. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection.
    Macagno F;
    Pediatr Med Chir; 2005; 27(3-4):70-7. PubMed ID: 16910454
    [No Abstract]   [Full Text] [Related]  

  • 35. North American synagis prophylaxis survey.
    Giusti R
    Pediatr Pulmonol; 2009 Jan; 44(1):96-8. PubMed ID: 19085922
    [No Abstract]   [Full Text] [Related]  

  • 36. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 37. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost minimisation of RSV prevention with palivizumab.
    Wills S; Simpson JH; Coutts J
    Arch Dis Child; 2006 Aug; 91(8):717. PubMed ID: 16861501
    [No Abstract]   [Full Text] [Related]  

  • 39. IMpact-RSV Study Group report.
    Zempsky WT; Schechter NL
    Pediatrics; 1999 Oct; 104(4 Pt 1):993-4; author reply 995. PubMed ID: 10532865
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.